Reuters Market Eye - Shares of Cadila Healthcare Ltd gain 4.7 percent after Bank of America-Merrill Lynch upgrades the stock to "buy" from "underperform" and raises its target to 1,000 rupees from 705 rupees, saying the worst is behind and earnings will accelerate from fiscal 2015.
The investment bank says it expects Cadila to get 20 or more drug approvals from the U.S. Food and Drug Administration, and that it expects domestic sales to recover in fiscal 2015.
Cadila's shares fell 10.4 percent in 2013 compared to the BSE healthcare index's gain of 22.5 percent in the same period.
(Reporting by Dipika Lalwani)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app